AlphaStocks
7.2
Consider Buy

ELI LILLY & Co (LLY)

As of Sep 20, 2026, ELI LILLY & Co (LLY) scores 7.2/10 on AlphaStocks' five-model composite, #11 of 168 Health Care stocks. At $1,152, LLY trades 76% above its model fair value of $656.

Health Care / Pharmaceuticals

S&P 500

$1,152.46

Above average across most dimensions. A solid candidate.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#11out of 168 in Health Care

Is ELI LILLY & Co a Good Investment in 2026?

ELI LILLY & Co (LLY) scores 7.2 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates ELI LILLY & Co as Strong (7/9). However, the Greenblatt Magic Formula model rates it Caution — Earnings yield 2.4% · ROC 58%. ELI LILLY & Co currently trades 76% above its estimated fair value of $656. ELI LILLY & Co ranks #11 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E50.2ROE82.0Market Cap1.0TDiv Yield0.5

Estimated Fair Value

$656.4876% above

Trading above estimated fair value. P/e of 50x implies high growth expectations. rapid eps growth (96%) partially justifies the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

7/9

Buffett

Strong

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

High PEG — growth premium · Stalwart

Greenblatt

Caution

Earnings yield 2.4% · ROC 58%

Frequently Asked Questions

Is ELI LILLY & Co (LLY) a good investment?
As of Sep 20, 2026, ELI LILLY & Co (LLY) scores 7.2/10 on AlphaStocks' five-model composite, #11 of 168 Health Care stocks. At $1,152, LLY trades 76% above its model fair value of $656. That score is above average across most investment dimensions.
What is ELI LILLY & Co's Piotroski F-Score?
ELI LILLY & Co's Piotroski F-Score status is Strong. The raw score is 7/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is LLY overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $656, LLY appears overvalued. The stock currently trades 76% above its estimated fair value. Trading above estimated fair value. P/e of 50x implies high growth expectations. rapid eps growth (96%) partially justifies the premium.
How does LLY compare to other Health Care stocks?
ELI LILLY & Co ranks #11 out of 168 stocks in the Health Care sector, placing it in the top 7% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about LLY?
AlphaStocks evaluates LLY using five proven investment models. Piotroski: Strong; Buffett: Strong; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 7.2/10.

Similar Stocks

AMPHACADAMRX

Compare LLY with

AMPH vs LLYACAD vs LLYAMRX vs LLYLLY vs MRKLLY vs VAL

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer